Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones
Top Cited Papers
Open Access
- 3 October 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Abstract
Intratumoral cellular heterogeneity necessitates multi-targeting therapies for improved clinical benefits in advanced malignancies. However, systematic identification of patient-specific treatments that selectively co-inhibit cancerous cell populations poses a combinatorial challenge, since the number of possible drug-dose combinations vastly exceeds what could be tested in patient cells. Here, we describe a machine learning approach, scTherapy, which leverages single-cell transcriptomic profiles to prioritize multi-targeting treatment options for individual patients with hematological cancers or solid tumors. Patient-specific treatments reveal a wide spectrum of co-inhibitors of multiple biological pathways predicted for primary cells from heterogenous cohorts of patients with acute myeloid leukemia and high-grade serous ovarian carcinoma, each with unique resistance patterns and synergy mechanisms. Experimental validations confirm that 96% of the multi-targeting treatments exhibit selective efficacy or synergy, and 83% demonstrate low toxicity to normal cells, highlighting their potential for therapeutic efficacy and safety. In a pan-cancer analysis across five cancer types, 25% of the predicted treatments are shared among the patients of the same tumor type, while 19% of the treatments are patient-specific. Our approach provides a widely-applicable strategy to identify personalized treatment regimens that selectively co-inhibit malignant cells and avoid inhibition of non-cancerous cells, thereby increasing their likelihood for clinical success.Keywords
All Related Versions
This publication has 72 references indexed in Scilit:
- Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinomaCancer Cell, 2023
- scDrug: From single-cell RNA-seq to drug response predictionComputational and Structural Biotechnology Journal, 2022
- Systematic review of computational methods for drug combination predictionComputational and Structural Biotechnology Journal, 2022
- Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinationsCancer Cell, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- Immunogenomic Landscape of Hematological MalignanciesCancer Cell, 2020
- Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityCell, 2019
- A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 ProfilesCell, 2017
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureCell, 2017
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015